

Arturo Loaiza-Bonilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4146302/publications.pdf>

Version: 2024-02-01

46
papers

1,033
citations

687363

13
h-index

414414

32
g-index

46
all docs

46
docs citations

46
times ranked

2335
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 993.	7.1	209
2	A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2012, 12, 199.	2.6	198
3	A phase 2 study of vorinostat in acute myeloid leukemia. <i>Haematologica</i> , 2009, 94, 1375-1382.	3.5	110
4	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. <i>Pancreatology</i> , 2015, 15, 667-673.	1.1	73
5	Neoadjuvant therapy for gastric cancer: current evidence and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 534-43.	1.4	58
6	Percutaneous Irreversible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1233-1239.e2.	0.5	51
7	Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. <i>Ecancermedicalscience</i> , 2014, 8, 479.	1.1	44
8	SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. <i>Endocrine-Related Cancer</i> , 2017, 24, L51-L55.	3.1	40
9	A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1-10.	1.4	39
10	Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution. <i>International Journal of Cancer</i> , 2016, 139, 1546-1556.	5.1	23
11	KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. <i>Cureus</i> , 2016, 8, e478.	0.5	20
12	Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3545-3545.	1.6	16
13	Differences in mutation rates between right- and left-sided colorectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 622-622.	1.6	14
14	Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 778-784.	1.4	13
15	Correction of Anemia in the Frail Elderly (CAFÉ): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia. <i>Blood</i> , 2012, 120, 5153-5153.	1.4	12
16	Prekallikrein Deficiency Presenting as Recurrent Cerebrovascular Accident: Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2012, 2012, 1-3.	0.4	10
17	Persistent Tn polyagglutination syndrome during febrile neutropenia: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 8.	0.8	8
18	A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 609-614.	2.3	8

#	ARTICLE	IF	CITATIONS
19	Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. <i>Current Opinion in Hematology</i> , 2010, 17, 104-109.	2.5	7
20	Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1065-1072.	2.4	7
21	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. <i>Cureus</i> , 2017, 9, e1258.	0.5	6
22	The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6779-6783.	1.9	6
23	Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110419.	3.2	6
24	Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced (LA) pancreatic carcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 324-324.	1.6	6
25	Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy. <i>Cureus</i> , 2017, 9, e1710.	0.5	6
26	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 201-211.	4.2	5
27	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021, 26, 651-659.	3.7	5
28	Lost in the Mist: Acute Adrenal Crisis Following Intranasal Fluticasone Propionate Overuse. <i>Case Reports in Medicine</i> , 2010, 2010, 1-4.	0.7	4
29	Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-5.	0.3	4
30	Concurrent Nab-paclitaxel and Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 469-474.	1.3	4
31	Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15213-e15213.	1.6	4
32	Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in postmenopausal Early Breast Cancer. <i>Clinical Medicine Insights Women's Health</i> , 2013, 6, CMWH.S8692.	0.6	3
33	Recurrent Thrombotic Thrombocytopenic Purpura-Like Syndrome as a Paraneoplastic Phenomenon in Malignant Peritoneal Mesothelioma: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-5.	0.3	2
34	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. <i>Breast Cancer Management</i> , 2012, 1, 105-108.	0.2	2
35	Pelvic Angiosarcoma Occurring in a Postmenopausal Female: Case Report and Review of the Literature. <i>Pathology and Oncology Research</i> , 2013, 19, 135-139.	1.9	2
36	Global survey of physicians' attitudes toward biologic and biosimilar therapies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18025-e18025.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOX.. Journal of Clinical Oncology, 2016, 34, 328-328.	1.6	2
38	Tracheal carcinoid presenting as refractory cervicgia in a postpartum patient: correlation versus epiphenomenon. Ear, Nose and Throat Journal, 2012, 91, E11-4.	0.8	2
39	Cardiotoxicity: Myocardium or Endothelium. Cureus, 2018, 10, e2994.	0.5	1
40	Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines.. Journal of Clinical Oncology, 2013, 31, e15007-e15007.	1.6	1
41	Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies. Hepatic Oncology, 2015, 2, 359-370.	4.2	0
42	Primary Care Challenges and the Educational Pipeline in the 21st Century. Southern Medical Journal, 2011, 104, 77-79.	0.7	0
43	Percutaneous irreversible electroporation (IRE) in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) to the liver: A retrospective analysis of the University of Miami experience.. Journal of Clinical Oncology, 2012, 30, 272-272.	1.6	0
44	Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX.. Journal of Clinical Oncology, 2014, 32, e15197-e15197.	1.6	0
45	Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma to uncover novel prognostic subgroups with differing patterns of genetic evolution.. Journal of Clinical Oncology, 2016, 34, e15043-e15043.	1.6	0
46	Tumor growth and regression rate constants from the CLARINET study as surrogate endpoints for progression free survival: A novel assessment approach in cancer therapy.. Journal of Clinical Oncology, 2018, 36, e24329-e24329.	1.6	0